ArticleActa dermato-venereologica2023
Impact of Type 1 Versus Type 2 Diabetes on Developing Herpes Zoster and Post-herpetic Neuralgia: A Population-based Cohort Study.
Article in Acta dermato-venereologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Construction and validation of a prediction system for postherpetic neuralgia: based on meta-analysis.Scientific reports · 2026Pooled it
- Predicting Treatment Response to Pulsed Radiofrequency in Postherpetic Neuralgia Using an Explainable Machine Learning Model.Journal of pain research · 2026Article
- National Trends and Disparities in Herpes Zoster Vaccination Among US Older Adults With Diabetes, 2008-2023.Pharmacoepidemiology and drug safety · 2025Article
- Causal effect of body mass index on herpes zoster and postherpetic neuralgia: A Mendelian randomization study.Medicine · 2025Article
- Genetically predicted amino acids related to neural regulation mediate the association between diabetes mellitus and postherpetic neuralgia: a Mendelian randomization study.Diabetology & metabolic syndrome · 2025Article
- Exploring the Link Between Diabetes, Herpes Zoster, and Post-Herpetic Neuralgia: Insights From Mendelian Randomization.Journal of pain research · 2025Article
- Article
- Genetic insights into the gut microbiota, herpes zoster, and postherpetic neuralgia: a bidirectional two-sample Mendelian randomization study.Frontiers in genetics · 2024Article
- Humoral Cytokine Levels in Patients with Herpes Zoster: A Meta-Analysis.Journal of pain research · 2024Review
- Causal effect of lifestyle and metabolic indicator with herpes zoster: a two-sample Mendelian randomization study.Frontiers in nutrition · 2024Article
- Impact of Herpes Zoster and Postherpetic Neuralgia on the Quality of Life in China: A Prospective Study.Clinical, cosmetic and investigational dermatology · 2024Article
- Analysis of Risk Factors and Development and Validation of a Dynamic Nomogram for Postherpetic Neuralgia: A Retrospective Study.Journal of pain research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes is associated with an increased risk of herpes zoster and postherpetic neuralgia. However, the association of type 1 diabetes with herpes zoster or postherpetic neuralgia remains unclear. This retrospective cohort study using Taiwan's Health Insurance Research Database included 199,566 patients with type 1 diabetes and 1,458,331 with type 2 diabetes, identified during the period 2000 to 2012. Patients with type 1 diabetes had a significantly higher risk of developing herpes zoster than those with type 2 diabetes (p < 0.001). Across all age groups, the impact of diabetes on herpes zoster was greater in type 1 than in type 2 diabetes. Patients with both type 1 and type 2 diabetes had a 1.45-fold higher risk of post-herpetic neuralgia than those without diabetes (hazard ratio 1.45, 95% confidence interval 1.28-1.65; hazard ratio 1.45, 95% confidence interval 1.37-1.52, respectively), and there was no difference between the 2 types of diabetes (hazard ratio 1.06; 95% confidence interval 0.93-1.21). The results recommend consideration of herpes zoster vaccination at an earlier age in patients with type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.